Tetraphase Pharmaceuticals Inc (TTPH) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.47 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.48. The company posted revenue of $1.20 million in the period, compared to analysts expectations of $2.05 million. The company’s revenue was down -63.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.72 EPS.
Many Wall Street Analysts have commented on Tetraphase Pharmaceuticals Inc. Shares were Reiterated by Wedbush on May 13, 2016 to “Outperform” and Lowered the Price Target to $ 4 from a previous price target of $8 .Gabelli & Co Downgraded Tetraphase Pharmaceuticals Inc on May 13, 2016 to ” Hold”, Price Target of the shares are set at $7.
Tetraphase Pharmaceuticals Inc closed down -0.18 points or -4.30% at $4.01 with 4,13,151 shares getting traded on Tusday. Post opening the session at $4.18, the shares hit an intraday low of $3.99 and an intraday high of $4.23 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Sep 10, 2015, John Craig Thompson (Chief Operating Officer) sold 10,000 shares at $44.08 per share price. According to the SEC, on Sep 3, 2015, Guy Macdonald (President and Chief Executive) sold 10,000 shares at $41.57 per share price. On Aug 17, 2015, David Charles Lubner (SVP and CFO) sold 9,500 shares at $42.92 per share price, according to the Form-4 filing with the securities and exchange commission.
Tetraphase Pharmaceuticals Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. The Company is engaged in developing its product candidate eravacycline which is a fully synthetic tetracycline derivative as a spectrum intravenous (IV) and an oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections including multidrug-resistant Gram-negative infections. TP-271 is a fully synthetic broad-spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271 the Company has conducted a number of in vitro toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens.